Stryker’s Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025. Latest Ratings for SYK Date Firm Action From To Jan 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 BTIG Maintains Buy Jan 2022 SVB Leerink Maintains Outperform View More Analyst Ratings for SYK…

Read More